Limits...
Adjunctive Treatment with Rhodiola Crenulata in Patients with Chronic Obstructive Pulmonary Disease--A Randomized Placebo Controlled Double Blind Clinical Trial.

Chuang ML, Wu TC, Wang YT, Wang YC, Tsao TC, Wei JC, Chen CY, Lin IF - PLoS ONE (2015)

Bottom Line: Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups.RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate.Further studies with a larger patient population are needed in order to confirm these findings.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary Medicine and Department of Critical Care Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

ABSTRACT

Unlabelled: Chronic obstructive pulmonary disease (COPD) is a low grade systemic inflammatory disease characterized by dyspnea and exercise intolerance even under standard therapy. Rhodiola crenulata (RC) has been shown to exert anti-inflammatory effects and to enhance exercise endurance, thereby having the potential to treat COPD. In this 12-week, randomized, double-blind, placebo-controlled clinical trial, 57 patients with stable moderate-to-severe COPD aged 70±8.8 years were given RC (250 mg twice/day) (n=38) or a placebo (250 mg twice/day) (n=19) in addition to their standard regimen. There were no significant differences in anthropometrics, quality of life, lung function, six-minute walk and incremental exercise tests between the two groups at enrollment. Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups. However, there were significant between-group differences in tidal volume and ventilation-CO2-output ratio at peak exercise (both p=.05), which were significantly related to peak work rate (both p<.0001). RC tended to protect against acute exacerbation of COPD (p=.1) but not other measurements. RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate. Further studies with a larger patient population are needed in order to confirm these findings.

Trial registration: ClinicalTrials.gov number NCT02242461.

No MeSH data available.


Related in: MedlinePlus

Relationship between tidal volume, ventilatory equivalent for CO2 output (eqCO2), and work rate at peak exercise.Left panel: Relationship between tidal volume and work rate at peak exercise in all patients over the treatment period (r = 0.61, p < .0001); Middle panel: Relationship between eqCO2 and work rate at peak exercise in all patients over the treatment period (r = -.54, p < .0001); Right panel: Relationship between eqCO2 and tidal volume at peak exercise in all patients over the treatment period (r = -.35, p < .01).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476627&req=5

pone.0128142.g006: Relationship between tidal volume, ventilatory equivalent for CO2 output (eqCO2), and work rate at peak exercise.Left panel: Relationship between tidal volume and work rate at peak exercise in all patients over the treatment period (r = 0.61, p < .0001); Middle panel: Relationship between eqCO2 and work rate at peak exercise in all patients over the treatment period (r = -.54, p < .0001); Right panel: Relationship between eqCO2 and tidal volume at peak exercise in all patients over the treatment period (r = -.35, p < .01).

Mentions: Over the 12-week study period, RC significantly improved the maximum workload from 85.2 (69% predicted) to 101.2 (79% predicted) watts (Fig 5, upper panels, both p < .05), and also modestly increased heart rate at rest (from 84 to 90 b/min, p = .02). RC also improved tidal volume at peak exercise (p < .01) and maintained the ventilatory equivalent for O2 uptake at peak exercise (E/ O2 peak) and ventilatory equivalent for CO2 output at peak exercise (E/ CO2 peak), although there was no significant change over the 12 weeks (p = .38 and .53, respectively). In contrast, the placebo significantly elevated the E/ O2 and E/ CO2 (p = .05 and .04, respectively). Between the two groups, RC improved the tidal volume and E/ CO2 at peak exercise (both p = .05), and both improvements were related to increases in workload (Fig 6, both p < .0001).


Adjunctive Treatment with Rhodiola Crenulata in Patients with Chronic Obstructive Pulmonary Disease--A Randomized Placebo Controlled Double Blind Clinical Trial.

Chuang ML, Wu TC, Wang YT, Wang YC, Tsao TC, Wei JC, Chen CY, Lin IF - PLoS ONE (2015)

Relationship between tidal volume, ventilatory equivalent for CO2 output (eqCO2), and work rate at peak exercise.Left panel: Relationship between tidal volume and work rate at peak exercise in all patients over the treatment period (r = 0.61, p < .0001); Middle panel: Relationship between eqCO2 and work rate at peak exercise in all patients over the treatment period (r = -.54, p < .0001); Right panel: Relationship between eqCO2 and tidal volume at peak exercise in all patients over the treatment period (r = -.35, p < .01).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476627&req=5

pone.0128142.g006: Relationship between tidal volume, ventilatory equivalent for CO2 output (eqCO2), and work rate at peak exercise.Left panel: Relationship between tidal volume and work rate at peak exercise in all patients over the treatment period (r = 0.61, p < .0001); Middle panel: Relationship between eqCO2 and work rate at peak exercise in all patients over the treatment period (r = -.54, p < .0001); Right panel: Relationship between eqCO2 and tidal volume at peak exercise in all patients over the treatment period (r = -.35, p < .01).
Mentions: Over the 12-week study period, RC significantly improved the maximum workload from 85.2 (69% predicted) to 101.2 (79% predicted) watts (Fig 5, upper panels, both p < .05), and also modestly increased heart rate at rest (from 84 to 90 b/min, p = .02). RC also improved tidal volume at peak exercise (p < .01) and maintained the ventilatory equivalent for O2 uptake at peak exercise (E/ O2 peak) and ventilatory equivalent for CO2 output at peak exercise (E/ CO2 peak), although there was no significant change over the 12 weeks (p = .38 and .53, respectively). In contrast, the placebo significantly elevated the E/ O2 and E/ CO2 (p = .05 and .04, respectively). Between the two groups, RC improved the tidal volume and E/ CO2 at peak exercise (both p = .05), and both improvements were related to increases in workload (Fig 6, both p < .0001).

Bottom Line: Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups.RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate.Further studies with a larger patient population are needed in order to confirm these findings.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary Medicine and Department of Critical Care Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

ABSTRACT

Unlabelled: Chronic obstructive pulmonary disease (COPD) is a low grade systemic inflammatory disease characterized by dyspnea and exercise intolerance even under standard therapy. Rhodiola crenulata (RC) has been shown to exert anti-inflammatory effects and to enhance exercise endurance, thereby having the potential to treat COPD. In this 12-week, randomized, double-blind, placebo-controlled clinical trial, 57 patients with stable moderate-to-severe COPD aged 70±8.8 years were given RC (250 mg twice/day) (n=38) or a placebo (250 mg twice/day) (n=19) in addition to their standard regimen. There were no significant differences in anthropometrics, quality of life, lung function, six-minute walk and incremental exercise tests between the two groups at enrollment. Over the 12 weeks, RC was well tolerated, significantly reduced triceps skin thickness (Δ=-1 mm, p=.04), change of FEV1 (4.5%, p=.03), and improved workload (Δ=10%, p=.01); although there were no significant differences in these factors between the two groups. However, there were significant between-group differences in tidal volume and ventilation-CO2-output ratio at peak exercise (both p=.05), which were significantly related to peak work rate (both p<.0001). RC tended to protect against acute exacerbation of COPD (p=.1) but not other measurements. RC did not improve the six-minute walk test distance but significantly improved tidal breathing and ventilation efficiency, most likely through improvements in work rate. Further studies with a larger patient population are needed in order to confirm these findings.

Trial registration: ClinicalTrials.gov number NCT02242461.

No MeSH data available.


Related in: MedlinePlus